Understand the source comparison
TB-4 Research Speed: Protocol Comparison
Observation Window 8–12 weeks 4–6 weeks Longer windows increase statistical power but require more resources; shorter windows risk false negatives if endpoint hasn't manifested Dosing Frequency Twice weekly Daily Daily dosing maintains receptor occupancy but i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Observation Window
- 8–12 weeks
- 4–6 weeks
- Longer windows increase statistical power but require more resources; shorter windows risk false negatives if endpoint hasn't manifested
- Dosing Frequency
- Twice weekly
- Daily
- Daily dosing maintains receptor occupancy but increases peptide cost and handling burden; twice-weekly reduces labour but extends timeline by 15–25%
- Administration Route
- Systemic (IV or distant SC)
- Peri-lesional subcutaneous
- Local administration maximises tissue concentration but limits systemic effects; systemic dosing provides broader coverage but dilutes local effects
- Animal Model Age
- Aged (18+ months)
- Young (8–12 weeks)
- Young models show faster effects but don't model age-related regenerative decline; aged models are clinically relevant but require 30–50% longer observation windows
- Peptide Storage
- Room temperature reconstituted vials
- Refrigerated (2–8°C) with freshly reconstituted aliquots
- Room temp storage degrades potency by 40–60% within 48 hours; refrigeration maintains >95% potency for 60 days but requires more rigorous cold chain management
- Professional Assessment
- Conservative protocols reduce risk of false negatives due to insufficient observation time but increase cost and resource burden. Accelerated protocols are feasible only when peptide integrity is verified, dosing is daily, and endpoints are molecular (gene expression) rather than structural (tissue morphology). The default recommendation: 6–8 week observation windows with daily dosing for vascular and wound healing endpoints.